The National Institutes of Health Microphysiological Systems (MPS) program, led by the National Center for Advancing Translational Sciences, is part of a joint effort on MPS development with the Defense Advanced Research Projects Agency and with regulatory guidance from FDA, is now in its final year of funding. The program has produced many tangible outcomes in tissue chip development in terms of stem cell differentiation, microfluidic engineering, platform development, and single and multi-organ systems—and continues to help facilitate the acceptance and use of tissue chips by the wider community. As the first iteration of the program draws to a close, this Commentary will highlight some of the goals met, and lay out some of the challenges uncovered that will remain to be addressed as the field progresses. The future of the program will also be outlined.
Impact statement
This work is important to the field as it outlines the progress and challenges faced by the NIH Microphysiological Systems program to date, and the future of the program. This is useful information for the field to be aware of, both for current program stakeholders and future awardees and partners.
ArrowsmithJ. Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov2011; 10: 87–87.
2.
ArrowsmithJ. Trial watch: phase II failures: 2008–2010. Nat Rev Drug Discov2011; 10: 328–9.
3.
CookDBrownDAlexanderRMarchRMorganPSatterthwaite G, PangalosMN. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov2014; 13: 419–31.
4.
FabreKMLivingstonCTagleDA. Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue. Exp Biol Med2014; 239: 1073–7.
5.
LivingstonCAFabreKMTagleDA. Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public–private partnerships. Comput Struct Biotechnol J2016; 14: 207–10.
6.
MarxUAnderssonTBBahinskiABielmanMBekenSCassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, RothA. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX2016; 33: 272–321.
7.
SweeneyLMShulerMLBabishJGGhanemA. A cell culture analogue of rodent physiology: Application to naphthalene toxicology. Toxicol In Vitro1995; 9: 307–16.
8.
SungJHDhimanAShulerML. A combined pharmacokinetic–pharmacodynamic (PK–PD) model for tumor growth in the rat with UFT administration. J Pharma Sci2009; 98: 1885–904.
9.
SinAChinKCJamilMFKostovYRaoGShulerML. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog2004; 20: 338–45.
HuhDMatthewsBDMammotoAMontoya-ZavalaMHsinHYIngberDE. Reconstituting organ-level lung functions on a chip. Science2010; 328: 1662–8.
12.
HuhDLeslieDCMatthewsBDFraserJPJurekSHamilton GA, Thorneloe KS, McAlexander MA, IngberDE. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med2012; 4: 159ra47–ra47.
13.
LianXHsiaoCWilsonGZhuKHazeltineLBAzarin SM, Raval KK, Zhang J, Kamp TJ, PalacekSP. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A2012; 109: E1848–E57.
14.
MathurALoskillPShaoKHuebschNHongSMarcus SG, Marks N, Mandegar M, Conklin BR, Lee LP, HealyKE. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep2015; 5: 8883–8883.
15.
AgarwalAGossJAChoAMcCainMLParkerKK. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip2013; 13: 3599–608.
16.
Vunjak-NovakovicGBhatiaSChenCHirschiK. HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther2013; 4: 1–6.
17.
CapulliAKTianKMehandruNBukhtaAChoudhurySFSuchyta M, ParkerKK. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip2014; 14: 3181–6.
18.
WangGMcCainMLYangLHeAPasqualiniFSAgarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, PuWT. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med2014; 20: 616–23.
19.
CapulliAKMacQueenLAO'ConnorBBDauthSParkerKK. Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro. Cardiovasc Pathol2016; 25: 316–24.
20.
HinsonJTChopraANafissiNPolacheckWJBensonCCSwist S, Gorham J, Yang L, Schafer S, Sheng CC, Haghighi A, Homsy J, Hubner N, Church G, Cook SA, Linke WA, Chen CS, Seidman JG, SeidmanCE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science2015; 349: 982–6.
21.
VernettiLASenutovitchNBoltzRDeBiasioRYing ShunTGough A, TaylorDL. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med2016; 241: 101–14.
22.
BrownJACodreanuSGShiMSherrodSDMarkovDANeely MD, Britt CM, Hoilett OS, Reiserer RS, Samson PC, McCawley LJ, Webb DJ, Bowman AB, McLean JA, WikswoJP. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit. J Neuroinflamm2016; 13: 306–306.
23.
SchwartzMPHouZPropsonNEZhangJEngstromCJSantos Costa V, Jiang P, Nguyen BK, Bolin JM, Daly W, Wang Y, Stewart R, Page CD, Murphy WL, ThomsonJA. Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. Proc Natl Acad Sci U S A2015; 112: 12516–21.
24.
BrownJAPensabeneVMarkovDAAllwardtVNeelyMDShi M, Britt CM, Hoilett OS, Yang Q, Brewer BM, Samson PC, McCawley LJ, May JM, Webb DJ, Li D, Bowman AB, Reiserer RS, WikswoJP. Recreating blood-brain barrier physiology and structure on chip: a novel neurovascular microfluidic bioreactor. Biomicrofluidics2015; 9: 054124–054124.
25.
BelairDGWhislerJAValdezJVelazquezJMolendaJAVickerman V, Lewis R, Daigh C, Hansen TD, Mann DA, Thomson JA, Griffith LG, Kamm RD, Schwartz MP, MurphyWL. Human vascular tissue models formed from human induced pluripotent stem cell derived endothelial cells. Stem Cell Rev2015; 11: 511–25.
26.
FernandezCEYenRWPerezSMBedellHWPovsicTJReichert WM, TruskeyGA. Human vascular microphysiological system for in vitro drug screening. Sci Rep2016; 6: 21579–21579.
27.
HsuY-HMoyaMLHughesCCWGeorgeaSCLeeAP. A microfluidic platform for generating large-scale nearly identical human microphysiological system arrays. Lab Chip2013; 13: 2990–8.
28.
SobrinoAPhanDTTDattaRWangXHacheySJRomero-López M, Gratton E, Lee AP, George SC, HughesCC. 3D microtumors in vitro supported by perfused vascular networks. Sci Rep2016; 6: 31589–31589.
29.
WeberEJChapronAChapronBDVoellingerJLLidbergKAYeung CK, Wang Z, Yamaura Y, Hailey DW, Neumann T, Shen DD, Thummel KE, Muczynski KA, Himmelfarb J, KellyEJ. Development of a microphysiological model of human kidney proximal tubule function. Kidney Int2016; 90: 627–37.
30.
ZhuJXuYRashediASPavoneMEKimJJWoodruff TK, BurdetteJE. Human fallopian tube epithelium co-culture with murine ovarian follicles reveals crosstalk in the reproductive cycle. Mol Hum Reprod. 2016;22:756–767.
31.
ShirureVSGeorgeSC. Design considerations to minimize the impact of drug absorption in polymer-based organ-on-a-chip platforms. Lab Chip. 2017;17:681–690.
32.
WheelerSEBorensteinJTClarkAMEbrahimkhaniMRFoxIJGriffith L, Inman W, Lauffenburger D, Nguyen T, Pillai VC, Prantil-Baun R, Stolz DB, Taylor D, Ulrich T, Venkataramanan R, Wells A, YoungC. All-human microphysical model of metastasis therapy. Stem Cell Res Ther2013; 4: S11–S.
33.
ClarkAMWheelerSETaylorDPPillaiVCYoungCLPrantil-Baun R, Nguyen T, Stolz DB, Borenstein JT, Lauffenburger DA, Venkataramanan R, Griffith LG, WellsA. A microphysiological system model of therapy for liver micrometastases. Exp Biol Med2014; 239: 1170–9.
34.
LarondaMMBurdetteJEKimJJWoodruffTK. Recreating the female reproductive tract in vitro using iPSC technology in a linked microfluidics environment. Stem Cell Res Ther2013; 4: S13–S.
35.
EddieSLKimJJWoodruffTKBurdetteJE. Microphysiological modeling of the reproductive tract: a fertile endeavor. Exp Biol Med2014; 239: 1192–202.
